Cancer 2015: A longitudinal whole-of-system study of genomic cancer medicine

David M. Thomas, Stephen Fox, Paula K. Lorgelly, David Ashley, Gary E. Richardson, Lara Lipton, John P Parisot, Mark Lucas, John McNeil, Michael Wright, for the Cancer 2015 Investigators

Research output: Contribution to journalReview ArticleOtherpeer-review

1 Citation (Scopus)

Abstract

Genomic cancer medicine promises revolutionary change in oncology. The impacts of 'personalized medicine', based upon a molecular classification of cancer and linked to targeted therapies, will extend from individual patient outcomes to the health economy at large. To address the 'whole-of-system' impact of genomic cancer medicine, we have established a prospective cohort of patients with newly diagnosed cancer in the state of Victoria, Australia, about whom we have collected a broad range of clinical, demographic, molecular, and patient-reported data, as well as data on health resource utilization. Our goal is to create a model for investigating public investment in genomic medicine that maximizes the cost:benefit ratio for the Australian community at large.

Original languageEnglish
Pages (from-to)1429-1432
Number of pages4
JournalDrug Discovery Today
Volume20
Issue number12
DOIs
Publication statusPublished - 1 Dec 2015

Cite this

Thomas, David M. ; Fox, Stephen ; Lorgelly, Paula K. ; Ashley, David ; Richardson, Gary E. ; Lipton, Lara ; Parisot, John P ; Lucas, Mark ; McNeil, John ; Wright, Michael ; for the Cancer 2015 Investigators. / Cancer 2015 : A longitudinal whole-of-system study of genomic cancer medicine. In: Drug Discovery Today. 2015 ; Vol. 20, No. 12. pp. 1429-1432.
@article{406702948bb043e491b6720979b6ecb8,
title = "Cancer 2015: A longitudinal whole-of-system study of genomic cancer medicine",
abstract = "Genomic cancer medicine promises revolutionary change in oncology. The impacts of 'personalized medicine', based upon a molecular classification of cancer and linked to targeted therapies, will extend from individual patient outcomes to the health economy at large. To address the 'whole-of-system' impact of genomic cancer medicine, we have established a prospective cohort of patients with newly diagnosed cancer in the state of Victoria, Australia, about whom we have collected a broad range of clinical, demographic, molecular, and patient-reported data, as well as data on health resource utilization. Our goal is to create a model for investigating public investment in genomic medicine that maximizes the cost:benefit ratio for the Australian community at large.",
author = "Thomas, {David M.} and Stephen Fox and Lorgelly, {Paula K.} and David Ashley and Richardson, {Gary E.} and Lara Lipton and Parisot, {John P} and Mark Lucas and John McNeil and Michael Wright and {for the Cancer 2015 Investigators}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.drudis.2015.10.009",
language = "English",
volume = "20",
pages = "1429--1432",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier",
number = "12",

}

Thomas, DM, Fox, S, Lorgelly, PK, Ashley, D, Richardson, GE, Lipton, L, Parisot, JP, Lucas, M, McNeil, J, Wright, M & for the Cancer 2015 Investigators 2015, 'Cancer 2015: A longitudinal whole-of-system study of genomic cancer medicine', Drug Discovery Today, vol. 20, no. 12, pp. 1429-1432. https://doi.org/10.1016/j.drudis.2015.10.009

Cancer 2015 : A longitudinal whole-of-system study of genomic cancer medicine. / Thomas, David M.; Fox, Stephen; Lorgelly, Paula K.; Ashley, David; Richardson, Gary E.; Lipton, Lara; Parisot, John P; Lucas, Mark; McNeil, John; Wright, Michael; for the Cancer 2015 Investigators.

In: Drug Discovery Today, Vol. 20, No. 12, 01.12.2015, p. 1429-1432.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Cancer 2015

T2 - A longitudinal whole-of-system study of genomic cancer medicine

AU - Thomas, David M.

AU - Fox, Stephen

AU - Lorgelly, Paula K.

AU - Ashley, David

AU - Richardson, Gary E.

AU - Lipton, Lara

AU - Parisot, John P

AU - Lucas, Mark

AU - McNeil, John

AU - Wright, Michael

AU - for the Cancer 2015 Investigators

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Genomic cancer medicine promises revolutionary change in oncology. The impacts of 'personalized medicine', based upon a molecular classification of cancer and linked to targeted therapies, will extend from individual patient outcomes to the health economy at large. To address the 'whole-of-system' impact of genomic cancer medicine, we have established a prospective cohort of patients with newly diagnosed cancer in the state of Victoria, Australia, about whom we have collected a broad range of clinical, demographic, molecular, and patient-reported data, as well as data on health resource utilization. Our goal is to create a model for investigating public investment in genomic medicine that maximizes the cost:benefit ratio for the Australian community at large.

AB - Genomic cancer medicine promises revolutionary change in oncology. The impacts of 'personalized medicine', based upon a molecular classification of cancer and linked to targeted therapies, will extend from individual patient outcomes to the health economy at large. To address the 'whole-of-system' impact of genomic cancer medicine, we have established a prospective cohort of patients with newly diagnosed cancer in the state of Victoria, Australia, about whom we have collected a broad range of clinical, demographic, molecular, and patient-reported data, as well as data on health resource utilization. Our goal is to create a model for investigating public investment in genomic medicine that maximizes the cost:benefit ratio for the Australian community at large.

UR - http://www.scopus.com/inward/record.url?scp=84949535602&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2015.10.009

DO - 10.1016/j.drudis.2015.10.009

M3 - Review Article

C2 - 26494144

AN - SCOPUS:84949535602

VL - 20

SP - 1429

EP - 1432

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 12

ER -